Media Center
In the media
AbilityPharma starts the Phase 2 with the anticancer drug ABTL0812
Diari de Sabadell
06/12/2016
Start of a clinical trial with a new drug for lung and endometiral cancer
La Vanguardia online
22/11/2016
European support to the oncology investigation
La Vanguardia
08/04/2015
Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma
Siege to cancer from Bellaterra
L'Econòmic - El Punt Avui
19/02/2013
The biomedical company Ability Pharmaceuticals obtains financing for a pioneering treatment for pancreatic and lung cancer in humans
Financing rounds of Catalan start-ups in 2012
Expansión
04/02/2013
After closing its financing round, Ability Pharmaceuticals – formerly AB-Therapeutics - split from the parent company AB-Biotics and changed its name
AB-Therapeutics raises one million euros and becomes Ability Pharmaceuticals.
Expansión
22/09/2012
AB-Therapeutics obtains resources to move forward in its R&D in oncology.
Diario Médico
21/09/2012
AB-Therapeutics closes a financing round of one million Euros and changes its name to Ability Pharmaceuticals.
Diari de Sabadell
19/09/2012
Abstract presented at the the meeting of the European Association for Cancer Research (AACR) in Barcelona (July 7-10, 2012)
07/07/2012
LATEST NEWS
18.09.2017
News
Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017
News
Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
15.12.2016
News
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016
News
Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016
News
Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015
News
Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014
News
Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
05.02.2014
News
ABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer + info
